Frontiers in Drug Discovery

Frontiers in Drug Discovery

Volume: 1

Erythropoietic Stimulating Agents

Indexed in: EBSCO.

The development of new erythropoietic stimulating agents (ESAs) has significantly increased in recent years. Researchers are focused on different and interesting concepts, namely, methods to increase ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



No Effect of Erythropoiesis-Stimulating Agents on Solid Tumour or Lymphoma Progression?

Pp. 255-270 (16)

Matti Aapro

Abstract

Erythropoiesis-stimulating agents (ESAs) are approved worldwide for treating anemia in cancer patients receiving chemotherapy. ESA-safety issues include thromboembolic events and there have been concerns about a possible induction of disease progression or increased mortality in cancer patients treated with these agents. This chapter discusses available evidence regarding this question. Clinical data and preclinical studies provide no convincing evidence that ESAs increase any risk related to the patient’s cancer when used within label. Assessment and definition of disease progression vary across studies, and preclinical work has often been conducted with inadequate methodology.

Keywords:

Disease progression, erythropoietin receptor, erythropoiesisstimulating agents.

Affiliation:

Multidisciplinary Oncology Institute, Clinique de Genolier, Route du Muids 3, P.O. Box 100, CH-1272 Genolier, Switzerland.